Crinetics reports Q2 2026 results alongside pending $10 billion Vertex acquisitionAug 3Quarterly updateCrinetics Pharmaceuticals, Incpaltusotine
Vertex to acquire Crinetics for $85 a share in $10 billion dealJul 6M&ACrinetics Pharmaceuticals, Incpaltusotine
Vertex to acquire Crinetics Pharmaceuticals for $85 per share in cashJul 6M&AVertex Pharmaceuticals Inc / Ma
Sign inSign in